Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00045617 · ClinicalTrials.gov registry record · Phase 2

S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer

A Phase 2 study, sponsored by SWOG Cancer Research Network.

Terminated
Registry status
Phase 2
Development phase
9
Enrollment target

NCT00045617: Clinical Trial Phase 2 study, sponsored by SWOG Cancer Research Network.

NCT00045617 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00045617, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.

TERMINATED
Registry status
Phase 2
Development phase
9 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who have limited-stage small cell lung cancer.

Primary Outcome

time from date of registration to date of death

Interventions

  • DRUG cisplatin
  • DRUG etoposide
  • RADIATION radiation therapy
  • BIOLOGICAL monoclonal antibody 11D10 anti-idiotype vaccine
  • BIOLOGICAL monoclonal antibody GD2 anti-idiotype vaccine

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2003-01
Est. Completion 2003-05
Phase Phase 2
SWOG Cancer Research Network

270 total trials

Why NCT00045617 stopped before completion

NCT00045617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.

NCT00045617 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00045617 about?

NCT00045617 is a clinical study titled "S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation thera...

What is the current status of trial NCT00045617?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2003-01. Estimated completion is 2003-05.

What interventions are being tested in trial NCT00045617?

The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), radiation therapy (RADIATION), monoclonal antibody 11D10 anti-idiotype vaccine (BIOLOGICAL), monoclonal antibody GD2 anti-idiotype vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00045617?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00045617's enrollment target sits among peer trials

9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00045617, the US trial registry maintained by the National Library of Medicine. NCT00045617 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.